Systemic pyoderma gangrenosum responding to infliximab and adalimumab

被引：74

作者：

Hubbard, VG ^{[1
]}

Friedmann, AC ^{[1
]}

Goldsmith, P ^{[1
]}

机构：

[1] Royal London Hosp, Dept Dermatol, London E1 1BB, England

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2005年 / 152卷 / 05期

关键词：

adalimumab; extracutaneous; human monoclonal antibodies; infliximab; pyoderma gangrenosum; tumour necrosis factor-alpha;

D O I：

10.1111/J.1365-2133.2005.06467.x

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Pyoderma gangrenosum (PG) is frequently associated with constitutional symptoms as part of a nonspecific inflammatory response. However, extracutaneous discrete aseptic neutrophilic infiltrates are extremely rare. We report a patient with idiopathic PG with splenic and psoas muscle involvement. His disease was extremely aggressive and was unresponsive to conventional immunosuppressive therapy. His cutaneous and extracutaneous PG cleared with infliximab and adalimumab.

引用

页码：1059 / 1061

页数：3

共 13 条

[1] Cavitating pulmonary infiltrate in an adolescent with pyoderma gangrenosum: A rarely recognized extracutaneous manifestation of a neutrophilic dermatosis [J].

Brown, TS ;

Marshall, GS ;

Callen, JP .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 43 (01) :108-112

[2] The incidence and management of infusion reactions to infliximab: A large center experience [J].

Cheifetz, A ;

Smedley, M ;

Martin, S ;

Reiter, M ;

Leone, G ;

Mayer, L ;

Plevy, S .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (06) :1315-1324

[3] OCULAR INVOLVEMENT IN PYODERMA GANGRENOSUM [J].

HAPPLE, R ;

SCHIFFER, HP ;

KOVARY, PM .

ARCHIVES OF DERMATOLOGY, 1977, 113 (11) :1612-1612

[4] Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody) [J].

Jenne, L ;

Sauter, B ;

Thumann, P ;

Hertl, M ;

Schuler, G .

BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (02) :380-382

[5]

Louis M, 2003, J RHEUMATOL, V30, P2557

[6] Neutrophilic myositis as an extracutaneous manifestation of neutrophilic dermatosis [J].

Marie, I ;

Levesque, H ;

Joly, P ;

Reumont, G ;

Courville, P ;

Baudrimont, M ;

Baubion, D ;

Cailleux, N ;

Courtois, H .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2001, 44 (01) :137-139

[7] Infliximab for peristomal pyoderma gangrenosum [J].

Mimouni, D ;

Anhalt, GJ ;

Kouba, DJ ;

Nousari, HC .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (04) :813-816

[8] Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease [J].

Regueiro, M ;

Valentine, J ;

Plevy, S ;

Fleisher, MR ;

Lichtenstein, GR .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (08) :1821-1826

[9] Pyoderma gangrenosum of the eyelid and acute rhinosinusitis [J].

Sidwell, RU ;

Patel, NN ;

Francis, N ;

Staughton, RCD .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (08) :680-682

[10]

Vadillo M, 1999, BRIT J DERMATOL, V141, P541

← 1 2 →